What is BioLoomics?
BioLoomics is at the forefront of advanced laboratory research, specializing in the development of Super-ADCs (Antibody-Drug Conjugates) and pioneering programs such as Directed Evolution. The company serves clients within the biotechnology and pharmaceutical sectors, emphasizing innovation and privacy in its operations. This enterprise-level funding positions BioLoomics to further its research and development initiatives.
How much funding has BioLoomics raised?
BioLoomics has raised a total of $8.7M across 1 funding round:
Angel/Seed
$8.7M
Angel/Seed (2023): $8.7M with participation from Horizons Ventures, Innovation Endeavors, and BoxOne Ventures
Key Investors in BioLoomics
Horizons Ventures
Horizons Ventures focuses on investing in deep science and technology aimed at advancing humanity towards a significantly improved future, supporting innovative projects with transformative potential.
Innovation Endeavors
Innovation Endeavors is an early-stage venture capital firm investing in visionary founders and transformational technologies, with a central thesis on the Super Evolution combining data, computation, and engineering.
BoxOne Ventures
BoxOne Ventures Inc operates within the Credit Cards & Transaction Processing industry, indicating a diverse investment portfolio that may extend to promising technology ventures.
What's next for BioLoomics?
With this major strategic investment, BioLoomics is poised for significant expansion. The capital will likely fuel further advancements in their Super-ADC technology and Directed Evolution programs, potentially accelerating their path to market. This backing from prominent investors suggests strong confidence in BioLoomics' scientific approach and its potential to disrupt the biotechnology and pharmaceutical landscapes.
See full BioLoomics company page
